Compare · CBLL vs MDT
CBLL vs MDT
Side-by-side comparison of CeriBell Inc. (CBLL) and Medtronic plc. (MDT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CBLL and MDT operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- MDT is the larger of the two at $122.09B, about 115.1x CBLL ($1.06B).
- Over the past year, CBLL is up 97.2% and MDT is down 1.1% - CBLL leads by 98.2 points.
- MDT has been more active in the news (35 items in the past 4 weeks vs 2 for CBLL).
- MDT has more recent analyst coverage (25 ratings vs 8 for CBLL).
- Company
- CeriBell Inc.
- Medtronic plc.
- Price
- $25.05-9.40%
- $94.77-0.74%
- Market cap
- $1.06B
- $122.09B
- 1M return
- +0.08%
- +2.12%
- 1Y return
- +97.17%
- -1.05%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NYSE
- IPO
- 2024
- News (4w)
- 2
- 35
- Recent ratings
- 8
- 25
Medtronic plc.
Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; AF ablation products; insertable cardiac monitor systems; mechanical circulatory support; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves; percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, percutaneous angioplasty balloons, and products to treat superficial venous diseases in the lower extremities. The Medical Surgical Portfolio segment offers surgical products, including surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases. The Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The Diabetes Operating Unit segment offers insulin pumps and consumables, and continuous glucose monitoring systems. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Latest CBLL
- Chief Technology Officer Woo Raymond exercised 4,887 shares at a strike of $3.65 and sold $119,145 worth of shares (4,887 units at $24.38) as part of a pre-agreed trading plan (SEC Form 4)
- Ceribell Receives FDA 510(k) Clearance for Quantitative EEG Trending and Amplitude-Integrated EEG Analysis
- President and CEO Chao Xingjuan sold $521,775 worth of shares (20,846 units at $25.03) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 746,345 units (SEC Form 4)
- Chief Financial Officer Blumberg Scott sold $21,150 worth of shares (846 units at $25.00) as part of a pre-agreed trading plan and exercised 846 shares at a strike of $9.41 (SEC Form 4)
- Senior VP, Finance and PAO Foehr David sold $224,451 worth of shares (9,255 units at $24.25) as part of a pre-agreed trading plan and exercised 7,500 shares at a strike of $4.70, decreasing direct ownership by 5% to 34,144 units (SEC Form 4)
- Chief Technology Officer Woo Raymond exercised 13,276 shares at a strike of $2.76 and sold $118,901 worth of shares (4,887 units at $24.33) as part of a pre-agreed trading plan, increasing direct ownership by 4% to 203,118 units (SEC Form 4)
- President and CEO Chao Xingjuan sold $973,079 worth of shares (39,540 units at $24.61) as part of a pre-agreed trading plan and exercised 25,000 shares at a strike of $4.70, decreasing direct ownership by 2% to 767,191 units (SEC Form 4)
- Chief Financial Officer Blumberg Scott exercised 652 shares at a strike of $9.41 and sold $16,300 worth of shares (652 units at $25.00) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Revenue Officer Manni Joseph S. sold $32,691 worth of shares (1,361 units at $24.02), decreasing direct ownership by 2% to 55,956 units (SEC Form 4) (tax liability)
- Senior VP, Finance and PAO Foehr David sold $44,425 worth of shares (1,852 units at $23.99) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 35,899 units (SEC Form 4) to cover withholding tax
Latest MDT
- SEC Form 4 filed by Medtronic plc.
- SEC Form 4 filed by Medtronic plc.
- Medtronic Named to TIME Best Inventions of 2026 List for Stealth AXiS™ surgical system and Corsano™* multi-parameter wearable
- MiniMed Completes Separation from Medtronic
- Medtronic Completes Separation of MiniMed Group, Inc.
- SEC Form 144 filed by Medtronic plc.
- Amendment: SEC Form SC TO-I/A filed by Medtronic plc.
- SEC Form 425 filed by Medtronic plc.
- Medtronic Announces Final Results of MiniMed Group, Inc. Exchange Offer
- Amendment: SEC Form SC TO-I/A filed by Medtronic plc.